Ipamorelin vs Sermorelin vs Tesamorelin: How the Research Compares

Two routes to growth hormone release

GH secretion from the pituitary is driven by two stimulatory pathways. The first is growth hormone-releasing hormone (GHRH), a 44-residue amidated peptide whose structure was established in the early 1980s from a human pancreatic tumor that had caused acromegaly¹. The second was found in reverse: synthetic GH secretagogues were shown in 1996 to act through a distinct G protein-coupled receptor in the pituitary and hypothalamus, GHS-R², and in 1999 its natural ligand was identified as ghrelin, an acylated 28-residue peptide from the stomach³.

Because these pathways are separate, a GH-releasing peptide combined with GHRH released GH synergistically in healthy men, more than either alone⁴. Ipamorelin belongs to the ghrelin-receptor class; sermorelin and tesamorelin belong to the GHRH class. That single fact explains most of the differences below.

Ipamorelin vs sermorelin vs tesamorelin at a glance

The table summarizes how the three peptides differ. Sources for each point are cited in the sections that follow.

Ipamorelin: the selective ghrelin-receptor agonist

Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, identified in a Novo Nordisk chemistry program among GHRP-1 analogs lacking its central Ala-Trp dipeptide⁵. In primary rat pituitary cells it released GH with potency and efficacy similar to GHRP-6, and antagonist studies placed its action at the GHRP receptor rather than the GHRH receptor. Its defining property was selectivity: in swine it did not raise ACTH or cortisol beyond levels seen with GHRH, even far above its GH-releasing range, whereas GHRP-6 and GHRP-2 did⁵.

Ghrelin-receptor agonists also affect gut motility, which shaped ipamorelin's clinical path. In a rat model of postoperative ileus, repeated intravenous ipamorelin increased fecal pellet output and food intake after abdominal surgery⁶. A phase 2, randomized, placebo-controlled trial in 117 patients undergoing bowel resection then found it well tolerated but with no significant difference from placebo in time to first tolerated meal or in secondary endpoints⁷. Ipamorelin has never been approved as a medicine; the ipamorelin page covers the compound in more detail.

Sermorelin: the shortest active GHRH

Sermorelin is GHRH(1-29)-NH2. Early sequencing work showed that the C-terminal part of the 44-residue hormone adds little to its activity: synthetic hpGRF(1-29)-NH2 matched the natural peptide in vitro⁸. A 1999 review describes sermorelin as the shortest synthetic peptide with the full biological activity of GHRH, specifically stimulating GH secretion from the anterior pituitary⁹.

Its research history is mainly diagnostic and pediatric. Sermorelin was used as a provocative test of pituitary GH reserve and studied in prepubertal children with idiopathic GH deficiency, where height velocity rose over 12 months but by less than reported with recombinant GH (somatropin)⁹. Researchers also explored GHRH and GH secretagogues as ways to restore GH secretion in aging, a line of work reviewed by Thorner and colleagues¹⁰.

In the US, sermorelin acetate was approved as Geref: a diagnostic presentation in 1990 and a presentation for idiopathic GH deficiency in children with growth failure in 1997. The manufacturer discontinued both in 2008, and in 2013 FDA determined they had not been withdrawn from sale for reasons of safety or effectiveness. See sermorelin for compound details.

Tesamorelin: the stabilized full-length GHRH

Tesamorelin (TH9507) keeps the full 44-residue human GHRH sequence and adds a trans-3-hexenoyl group to Tyr1. Non-clinical studies showed that this makes it resistant to dipeptidyl aminopeptidase-IV, slows its degradation in rat, dog and human plasma and prolongs its plasma elimination compared with native GHRH(1-44)-NH2¹¹.

It has the deepest clinical record of the three. In the 2007 phase 3 trial, 412 people with HIV and abdominal fat accumulation were randomized to tesamorelin or placebo for 26 weeks; visceral adipose tissue fell 15.2% versus a 5.0% rise with placebo, and IGF-1 rose 81%¹². Later randomized work reported a 37% relative reduction in hepatic fat fraction in people with HIV and fatty liver disease¹³, and a 20-week controlled trial in 152 older adults with or without mild cognitive impairment reported a favorable effect on executive function¹⁴.

Tesamorelin is the active ingredient of Egrifta (now Egrifta SV and Egrifta WR), first approved by FDA in 2010 and labeled for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. The research peptide is not that medicine; see tesamorelin.

Why researchers compare and combine them

The two classes are compared because they probe different control points. A GHRH analog tests the pituitary's response to its main hypothalamic driver; a ghrelin-receptor agonist tests a parallel pathway that also operates in the hypothalamus² and the gut⁶. GH secretagogue research has emphasized restoring pulsatile GH release, which IGF-1 feedback keeps within limits¹⁵.

Combining one of each draws on the synergy first shown with GHRH and a GH-releasing peptide in humans⁴. That rationale underlies research blends such as Tesamorelin + Ipamorelin and CJC-1295 + Ipamorelin. No published study has tested either blend as such; the evidence is for each component and for the general principle.

Limitations of the evidence

• No head-to-head trials compare ipamorelin, sermorelin and tesamorelin; every difference here comes from separate studies in different populations.
• Tesamorelin's human data are concentrated in adults with HIV and central fat accumulation^12,13, and its label notes that long-term cardiovascular safety has not been established.
• Sermorelin's clinical literature is older and mostly pediatric⁹.
• Ipamorelin's selectivity data come from rats and swine⁵, and its one published efficacy trial was negative⁷.
• None of these studies used research-grade material. Identity and purity of a research peptide have to be confirmed lot by lot; every Peptides Only lot ships with a lot-matched certificate of analysis in the COA library.